{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:18:23Z","timestamp":1794745103070,"version":"4.9.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ-DRO-VFN64165"],"award-info":[{"award-number":["MH CZ-DRO-VFN64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119980","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:09:57Z","timestamp":1791558597000},"page":"119980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacokinetics and immunomodulatory effects of selective orexin 1 receptor agonist OXA 17\u201333: PBMC responses, HPA axis activation, and outcomes in the collagen-induced arthritis model"],"prefix":"10.1016","volume":"204","author":[{"given":"Daniel","family":"Str\u00e1nsk\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u0160teigerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-7528","authenticated-orcid":false,"given":"Petr","family":"Kozl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-8844","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"K\u0159\u00ed\u017eek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Sklen\u00e1rov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"Paulusov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-1663","authenticated-orcid":false,"given":"Pavel","family":"Ry\u0161\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Kupcov\u00e1 Skaln\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-9423","authenticated-orcid":false,"given":"Sara","family":"Merdita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane\u017eka","family":"Klou\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesia","family":"Symkanych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0102-856X","authenticated-orcid":false,"given":"Jan","family":"Hlav\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zde\u0148ka","family":"Doubkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-738X","authenticated-orcid":false,"given":"Martin","family":"\u0160\u00edma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5357-7562","authenticated-orcid":false,"given":"Ond\u0159ej","family":"Slana\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119980_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fendo.2013.00018","article-title":"The physiological role of orexin\/hypocretin neurons in the regulation of sleep\/wakefulness and neuroendocrine functions","volume":"4","author":"Inutsuka","year":"2013","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119980_bib2","doi-asserted-by":"crossref","unstructured":"Lawrence, A.J., Behavioral Neuroscience of Orexin\/Hypocretin. 2017.","DOI":"10.1007\/978-3-319-57535-3"},{"key":"10.1016\/j.biopha.2026.119980_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171051","article-title":"The present and future of synthetic orexin receptor agonists","volume":"167","author":"Saitoh","year":"2023","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.biopha.2026.119980_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119980_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnmol.2018.00220","article-title":"The Orexin\/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2026.119980_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.812359","article-title":"Orexin Signaling: A Complex, Multifaceted Process","volume":"16","author":"Dale","year":"2022","journal-title":"Front. Cell. Neurosci."},{"issue":"16","key":"10.1016\/j.biopha.2026.119980_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164849","article-title":"Orexins\/Hypocretins and Cancer: A Neuropeptide as Emerging Target","volume":"26","author":"Alain","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","article-title":"International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology","volume":"76","author":"Kukkonen","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2026.119980_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000514962","article-title":"Cellular Signaling Mechanisms of Hypocretin\/Orexin","volume":"45","author":"Kukkonen","year":"2021","journal-title":"Front. Neurol. Neurosci."},{"key":"10.1016\/j.biopha.2026.119980_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.931970","article-title":"The Orexin receptors: Structural and anti-tumoral properties","volume":"13","author":"Couvineau","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119980_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fnins.2020.00691","article-title":"Evolution of Orexin Neuropeptide System: Structure and Function","volume":"14","author":"Soya","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2026.119980_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1831913","article-title":"The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications","volume":"17","author":"Stransky","year":"2026","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1177\/0961203318778767","article-title":"Cerebrospinal fluid orexin-A levels in systemic lupus erythematosus patients presenting with excessive daytime sleepiness","volume":"27","author":"Suzuki","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24170","article-title":"Investigation of serum levels of orexin-A, transforming growth factor beta, and leptin in patients with multiple sclerosis","volume":"36","author":"Moharami","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00393-023-01462-y","article-title":"The role of orexin in fatigue and sleep quality in patients with primary Sjogren's syndrome","volume":"83","author":"Sandikci","year":"2024","journal-title":"Z. Rheumatol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119980_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jns.2014.08.041","article-title":"Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients","volume":"346","author":"Kucukali","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10792-019-01157-x","article-title":"Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event","volume":"40","author":"Turkoglu","year":"2020","journal-title":"Int. Ophthalmol."},{"issue":"44","key":"10.1016\/j.biopha.2026.119980_bib19","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.3748\/wjg.v27.i44.7582","article-title":"Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions","volume":"27","author":"Couvineau","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib20","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.bbadis.2018.08.023","article-title":"Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A","volume":"1864","author":"Messal","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"12","key":"10.1016\/j.biopha.2026.119980_bib21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2009.264","article-title":"Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications","volume":"66","author":"Kanbayashi","year":"2009","journal-title":"Arch. Neurol."},{"issue":"7-08","key":"10.1016\/j.biopha.2026.119980_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.18071\/isz.75.0223","article-title":"Comparison of orexin-A and neurofilament light chain levels in patients with relapsing-remitting multiple sclerosis: a pilot study","volume":"75","author":"Saruhan","year":"2022","journal-title":"Ideggyogy. Sz."},{"issue":"8","key":"10.1016\/j.biopha.2026.119980_bib23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1080\/13548506.2019.1707240","article-title":"A comparative study of the nature and magnitude of problems sleeping in inflammatory bowel disease (IBD) compared to healthy controls","volume":"25","author":"Scott","year":"2020","journal-title":"Psychol. Health Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12974-019-1447-y","article-title":"Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation","volume":"16","author":"Becquet","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2026.119980_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.biopha.2018.07.159","article-title":"Orexin A may suppress inflammatory response in fibroblast-like synoviocytes","volume":"107","author":"Sun","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119980_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yfrne.2018.06.003","article-title":"Orexins and stress","volume":"51","author":"Grafe","year":"2018","journal-title":"Front. Neuroendocrinol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166230","article-title":"Orexin-A alleviates astrocytic apoptosis and inflammation via inhibiting OX1R-mediated NF-kappaB and MAPK signaling pathways in cerebral ischemia\/reperfusion injury","volume":"1867","author":"Xu","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib28","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1080\/21691401.2019.1614014","article-title":"Orexin A ameliorates HBV X protein-induced cytotoxicity and inflammatory response in human hepatocytes","volume":"47","author":"Wang","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119980_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.07.017","article-title":"The protective effects of orexin a against high glucose-induced activation of NLRP3 inflammasome in human vascular endothelial cells","volume":"672","author":"Zhang","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12031-013-0165-7","article-title":"Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling","volume":"52","author":"Sokolowska","year":"2014","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2026.119980_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.mcn.2016.07.003","article-title":"Orexin A attenuates palmitic acid-induced hypothalamic cell death","volume":"75","author":"Duffy","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2012.07.002","article-title":"Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model","volume":"524","author":"Butterick","year":"2012","journal-title":"Neurosci. Lett."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.biopha.2026.119980_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108013","article-title":"Recent perspectives on orexin\/hypocretin promotion of addiction-related behaviors","volume":"168","author":"Hopf","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ijnp\/pyab078","article-title":"Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant","volume":"25","author":"Jha","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119980_bib37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa2405847","article-title":"Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1","volume":"392","author":"Dauvilliers","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119980_bib38","article-title":"The Race Toward Orexin Agonists Targeting Narcolepsy\u2019s Root Cause","author":"Arnett","year":"2025","journal-title":"Sleep. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis","volume":"32","author":"van der Woude","year":"2018","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119980_bib41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"7-","key":"10.1016\/j.biopha.2026.119980_bib42","first-page":"S128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am. J. Manag. Care"},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrrheum.2009.178","article-title":"G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis","volume":"5","author":"Cornish","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119980_bib46","first-page":"575","article-title":"Collagen induced arthritis as an experimental model for rheumatoid arthritis","volume":"97","author":"Holmdahl","year":"1989","journal-title":"Immunogenet. Pathog. Autoimmun. APMIS"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14712\/fb2023069020041","article-title":"Pathogenesis of Collagen-Induced Arthritis: Role of Immune Cells with Associated Cytokines and Antibodies, Comparison with Rheumatoid Arthritis","volume":"69","author":"Steigerova","year":"2023","journal-title":"Folia Biol. (Praha)"},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib48","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240226","article-title":"Simple, streamlined, cost-effective cDNA synthesis method from cell cultures","volume":"15","author":"Stransky","year":"2025","journal-title":"Open. Biol."},{"key":"10.1016\/j.biopha.2026.119980_bib49","unstructured":"EMA, Guideline on bioanalytical method validation. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation [Accesed March 15, 2025]."},{"key":"10.1016\/j.biopha.2026.119980_bib50","series-title":"A protocol for successfully inducing collagen-induced arthritis (CIA) in rats","author":"Chondrex","year":"2015"},{"key":"10.1016\/j.biopha.2026.119980_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2105-13-134","article-title":"Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction","volume":"13","author":"Ye","year":"2012","journal-title":"BMC Bioinforma."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.biopha.2026.119980_bib53","unstructured":"Str\u00e1nsk\u00fd, D.N., S. Tabarestani, P. Bazyuk, M, Orexin [open data repository]. OSF. 2026. Available from: https:\/\/osf.io\/afx5p\/overview?view_only=53acb2e4365a4b30be28f9b7424c1a53. https:\/\/doi.org\/10.17605\/OSF.IO\/AFX5P."},{"key":"10.1016\/j.biopha.2026.119980_bib54","unstructured":"The Human protein Atlas. Available from: https:\/\/www.proteinatlas.org\/ [Accessed December 8, 2025]."},{"issue":"6220","key":"10.1016\/j.biopha.2026.119980_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.biopha.2026.119980_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci. Adv."},{"issue":"6472","key":"10.1016\/j.biopha.2026.119980_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells","volume":"366","author":"Uhlen","year":"2019","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib58","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib59","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib60","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1210\/me.2004-0167","article-title":"Genomic organization of mouse orexin receptors: characterization of two novel tissue-specific splice variants","volume":"18","author":"Chen","year":"2004","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brainres.2006.05.054","article-title":"Differential expression of mouse orexin receptor type-2 (OX2R) variants in the mouse brain","volume":"1103","author":"Chen","year":"2006","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/BJ20091755","article-title":"Genomic organization and regulation of the human orexin (hypocretin) receptor 2 gene: identification of alternative promoters","volume":"427","author":"Chen","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2026.119980_bib63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fendo.2019.00219","article-title":"Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier","volume":"10","author":"Tunisi","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119980_bib64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neulet.2015.08.033","article-title":"Role of orexin A signaling in dietary palmitic acid-activated microglial cells","volume":"606","author":"Duffy","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib65","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/STROKEAHA.112.681700","article-title":"Mitigation of murine focal cerebral ischemia by the hypocretin\/orexin system is associated with reduced inflammation","volume":"44","author":"Xiong","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bph.12245","article-title":"Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands","volume":"171","author":"Mould","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib67","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2026.119980_bib69","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bph.17422","article-title":"Pharmacodynamics of the orexin type 1 (OX(1)) receptor in colon cancer cell models: A two-sided nature of antagonistic ligands resulting from partial dissociation of Gq","volume":"182","author":"Gratio","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib70","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1742-1241.2010.02470.x","article-title":"How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes","volume":"64","author":"Arnolds","year":"2010","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib71","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib72","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119980_bib73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-199920040-00003","article-title":"A risk-benefit assessment of oxytocics in obstetric practice","volume":"20","author":"Winkler","year":"1999","journal-title":"Drug. Saf."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib74","doi-asserted-by":"crossref","first-page":"fcab050","DOI":"10.1093\/braincomms\/fcab050","article-title":"Pre-treatment of blood samples reveal normal blood hypocretin\/orexin signal in narcolepsy type 1","volume":"3","author":"HM","year":"2021","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0022-3565(24)38126-1","article-title":"Orexin A but not orexin B rapidly enters brain from blood by simple diffusion","volume":"289","author":"Kastin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.regpep.2004.02.004","article-title":"Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat","volume":"119","author":"Ehrstrom","year":"2004","journal-title":"Regul. Pept."},{"issue":"7","key":"10.1016\/j.biopha.2026.119980_bib77","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/jps.21604","article-title":"2nd, Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.","volume":"98","author":"Dhuria","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119980_bib78","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1210\/jc.2004-1408","article-title":"Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas in man","volume":"90","author":"Ehrstrom","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119980_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neulet.2016.05.053","article-title":"Food consumption and activity levels increase in rats following intranasal Hypocretin-1","volume":"627","author":"Dhuria","year":"2016","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.biopha.2026.119980_bib80","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00001756-200006260-00034","article-title":"Centrally administered orexin\/hypocretin activates HPA axis in rats","volume":"11","author":"Kuru","year":"2000","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib81","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1006\/bbrc.2000.2412","article-title":"Possible involvement of orexin in the stress reaction in rats","volume":"270","author":"Ida","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2826.2001.00672.x","article-title":"The central effects of orexin-A in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats","volume":"13","author":"Russell","year":"2001","journal-title":"J. Neuroendocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119980_bib83","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1046\/j.1365-2826.2000.00572.x","article-title":"Effects of orexins on the hypothalamic-pituitary-adrenal system","volume":"12","author":"Jaszberenyi","year":"2000","journal-title":"J. Neuroendocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2826.2001.00655.x","article-title":"Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats","volume":"13","author":"Al-Barazanji","year":"2001","journal-title":"J. Neuroendocrinol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119980_bib85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1365-2826.2003.01045.x","article-title":"Hypothalamic-pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats","volume":"15","author":"Brunton","year":"2003","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1385\/ENDO:26:2:099","article-title":"Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity","volume":"26","author":"Moreno","year":"2005","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib87","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.neures.2006.11.009","article-title":"Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats","volume":"57","author":"Chang","year":"2007","journal-title":"Neurosci. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119980_bib88","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.neuroscience.2008.09.042","article-title":"I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation","volume":"157","author":"Ito","year":"2008","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib89","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1097\/CCM.0b013e31828e9843","article-title":"Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis","volume":"41","author":"Deutschman","year":"2013","journal-title":"Crit. Care Med."},{"issue":"4-6","key":"10.1016\/j.biopha.2026.119980_bib90","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0960-0760(99)00110-7","article-title":"Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signaling cascade","volume":"70","author":"Malendowicz","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2220\/biomedres.21.89","article-title":"Modulatory effects of orexins on the function of rat pituitary-adrenocortical axis under basal and stressful conditions","volume":"21","author":"Nowak","year":"2000","journal-title":"Biomed. Res. -Tokyo"},{"issue":"4","key":"10.1016\/j.biopha.2026.119980_bib92","first-page":"401","article-title":"Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland","volume":"7","author":"Malendowicz","year":"2001","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib93","first-page":"713","article-title":"Effects of orexins A and B on the secretory and proliferative activity of immature and regenerating rat adrenal glands","volume":"16","author":"Malendowicz","year":"2001","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.biopha.2026.119980_bib94","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.21055","article-title":"Peripherally administered orexin improves survival of mice with endotoxin shock","volume":"5","author":"Ogawa","year":"2016","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib95","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/jcem.86.2.7233","article-title":"Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade","volume":"86","author":"Mazzocchi","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119980_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0167-0115(01)00356-1","article-title":"Effects of orexin on cultured porcine adrenal medullary and cortex cells","volume":"104","author":"Nanmoku","year":"2002","journal-title":"Regul. Pept."},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib97","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jsbmb.2005.05.003","article-title":"Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor","volume":"96","author":"Ziolkowska","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119980_bib98","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1210\/en.2007-1739","article-title":"Orexins stimulate steroidogenic acute regulatory protein expression through multiple signaling pathways in human adrenal H295R cells","volume":"149","author":"Ramanjaneya","year":"2008","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/JOE-08-0536","article-title":"Orexin-stimulated MAP kinase cascades are activated through multiple G-protein signalling pathways in human H295R adrenocortical cells: diverse roles for orexins A and B","volume":"202","author":"Ramanjaneya","year":"2009","journal-title":"J. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119980_bib100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3892\/ijmm.2014.1959","article-title":"Orexin-A stimulates 3beta-hydroxysteroid dehydrogenase expression and cortisol production in H295R human adrenocortical cells through the AKT pathway","volume":"34","author":"Chang","year":"2014","journal-title":"Int. J. Mol. Med."},{"issue":"16","key":"10.1016\/j.biopha.2026.119980_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612559","article-title":"Interaction of Orexin and Bone Morphogenetic Proteins in Steroidogenesis by Human Adrenocortical Cells","volume":"24","author":"Soejima","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166844","article-title":"Orexin-A\/OX1R is involved in regulation of autophagy to promote cortisol secretion in adrenocortical cell","volume":"1870","author":"Guo","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib103","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1210\/jcem.86.10.7921","article-title":"Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis","volume":"86","author":"Randeva","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2026.119980_bib104","doi-asserted-by":"crossref","first-page":"R1601","DOI":"10.1152\/ajpregu.91034.2008","article-title":"Hypocretin\/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells","volume":"297","author":"Wenzel","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2026.119980_bib105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2013.12.045","article-title":"The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy","volume":"262","author":"Weinhold","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib106","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1152\/jn.00452.2021","article-title":"Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans","volume":"127","author":"Meusel","year":"2022","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.biopha.2026.119980_bib107","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fnagi.2019.00362","article-title":"Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats","volume":"11","author":"Calva","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib108","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jnc.14279","article-title":"Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1)","volume":"145","author":"Calva","year":"2018","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib109","article-title":"Intranasal Orexin After Cardiac Arrest Leads to Increased Electroencephalographic Gamma Activity and Enhanced Neurologic Recovery in Rats","volume":"3","author":"Sherman","year":"2021","journal-title":"Crit. Care Explor."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib110","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.sleep.2011.06.015","article-title":"Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy","volume":"12","author":"Baier","year":"2011","journal-title":"Sleep. Med."},{"issue":"Pt 10","key":"10.1016\/j.biopha.2026.119980_bib111","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awn193","article-title":"Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)","volume":"131","author":"Baier","year":"2008","journal-title":"Brain"},{"issue":"52","key":"10.1016\/j.biopha.2026.119980_bib112","doi-asserted-by":"crossref","first-page":"14239","DOI":"10.1523\/JNEUROSCI.3878-07.2007","article-title":"Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates","volume":"27","author":"Deadwyler","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2026.119980_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114491","article-title":"Nasal administration of orexin A partially rescues dizocilpine-induced cognitive impairments in female C57BL\/6 J mice","volume":"450","author":"Durairaja","year":"2023","journal-title":"Behav. Brain Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119554","article-title":"Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab","volume":"24","author":"Blais","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119980_bib115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1139\/cjpp-2014-0258","article-title":"Effect of orexin-A (hypocretin-1) on hyperalgesic and cachectic manifestations of experimentally induced rheumatoid arthritis in rats","volume":"92","author":"Mohamed","year":"2014","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493739","article-title":"Influence of Orexinergic System on Survival in Septic Rats","volume":"77","author":"Takekawa","year":"2019","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopha.2026.119980_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114262","article-title":"Centrally administered orexin prevents lipopolysaccharide and colchicine induced lethality via the vagal cholinergic pathway in a sepsis model in rats","volume":"182","author":"Igarashi","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119980_bib118","article-title":"orexin B alleviates sepsis-associated lung injury through the attenuation of pulmonary endothelial barrier dysfunction by regulating the rho-associated coiled-coil containing protein kinase 2\/zonula occludens-1 (ROCK2\/ZO-1) axis","author":"Wang","year":"2024","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib119","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neures.2010.06.010","article-title":"The effect of orexin-A on the pathological mechanism in the rat focal cerebral ischemia","volume":"68","author":"Kitamura","year":"2010","journal-title":"Neurosci. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12974-020-01841-1","article-title":"Orexin A alleviates neuroinflammation via OXR2\/CaMKKbeta\/AMPK signaling pathway after ICH in mice","volume":"17","author":"Li","year":"2020","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib121","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/ALN.0b013e318206ff6f","article-title":"Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat","volume":"114","author":"Yuan","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopha.2026.119980_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111105","article-title":"Orexin A protects against cerebral ischemia-reperfusion injury by enhancing reperfusion in ischemic cortex via HIF-1alpha-ET-1\/eNOS pathway","volume":"218","author":"Zhu","year":"2024","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.biopha.2026.119980_bib123","article-title":"The role of orexin A in the pathogenesis of ischaemic stroke at high altitude","author":"Zhu","year":"2025","journal-title":"Exp. Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119980_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182707","article-title":"Intranasal post-cardiac arrest treatment with orexin-A facilitates arousal from coma and ameliorates neuroinflammation","volume":"12","author":"Modi","year":"2017","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(02)00176-3","article-title":"Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat","volume":"324","author":"Irving","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2026.119980_bib126","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/2045-9912.215750","article-title":"The role of nitric oxide in stroke","volume":"7","author":"Chen","year":"2017","journal-title":"Med. Gas. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib127","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jnr.24101","article-title":"Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury","volume":"96","author":"Greco","year":"2018","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119980_bib128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-024-03111-w","article-title":"Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice","volume":"21","author":"Guo","year":"2024","journal-title":"J. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.biopha.2026.119980_bib129","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70096","article-title":"Orexin-A Attenuates the Inflammatory Response in Sepsis-Associated Encephalopathy by Modulating Oxidative Stress and Inhibiting the ERK\/NF-kappaB Signaling Pathway in Microglia and Astrocytes","volume":"30","author":"Guo","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2026.119980_bib130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2016.01.001","article-title":"Role of orexin-A in experimental autoimmune encephalomyelitis","volume":"291","author":"Fatemi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119980_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105009","article-title":"The orexin system in the enteric nervous system of the bottlenose dolphin (Tursiops truncatus)","volume":"9","author":"Gatta","year":"2014","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib132","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.acthis.2011.02.006","article-title":"Localization of the orexin system in the gastrointestinal tract of fallow deer","volume":"114","author":"Dall'Aglio","year":"2012","journal-title":"Acta Histochem."},{"issue":"2","key":"10.1016\/j.biopha.2026.119980_bib133","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rvsc.2008.07.001","article-title":"Immunohistochemical identification and localization of orexin A and orexin type 2 receptor in the horse gastrointestinal tract","volume":"86","author":"Dall'aglio","year":"2009","journal-title":"Res. Vet. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:50:44Z","timestamp":1794743444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226010164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":133,"alternative-id":["S0753332226010164"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119980","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and immunomodulatory effects of selective orexin 1 receptor agonist OXA 17\u201333: PBMC responses, HPA axis activation, and outcomes in the collagen-induced arthritis model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119980"}}